Nilotinib is a selective BCR-ABL tyrosine kinase inhibitor that blocks the activity of the abnormal protein causing uncontrolled cell proliferation in Ph+ CML. It prevents division and spread of leukemic cells, promoting full or partial remission.
Nilotinib has demonstrated efficacy in international clinical trials (ENESTnd, ENEST1st), achieving higher molecular and cytogenetic remission rates compared to imatinib. Recommended by leading hematology societies (NCCN, ESMO) for Ph+ CML therapy.
The drug inhibits BCR-ABL protein activity, suppresses leukemic cell growth, and prevents disease progression.
Capsules are taken orally, usually twice daily, 1 hour before or 2 hours after meals, with a full glass of water. Dosage is individualized based on disease stage, tolerance, and blood tests. Treatment is conducted under oncologist supervision.
Contraindications
Side effects
